Broomfield-based Aclarion, a healthcare technology company, has completed a $10.4 million financing round at $5.18 per share. This clean capital raise significantly strengthens the company’s financial position, preserves its capital structure, and extends its operational timeline, allowing continued development of its pain identification technology.
The increased capital is aimed at enhancing Aclarion’s commercialization efforts, generating clinical evidence, and establishing strategic partnerships ahead of potential additional insurance coverage for its technology. As of January 12, 2026, the company reported having $21.6 million in cash and no debt, projecting its cash runway to extend into 2028 based on current plans.
Brent Ness, Chief Executive Officer of Aclarion, said, “We have transformed Aclarion’s balance sheet over the past year and positioned the Company for long-term value creation with a pristine capital structure. This financing clearly de-risks our ability to reach significant milestones within the timeline of our cash runway.”
Aclarion is currently focused on advancing its clinical trials and expanding its market access, while also collaborating with various payers to pursue wider reimbursement coverage for its technology. The company plans to accelerate enrollment in its clinical trials and support broader clinician education initiatives.
For more information, please visit GlobeNewswire.
